ArticleInvestigative ophthalmology & visual science2026
Theophylline Inhibits Capillary Degeneration in Early Diabetic Retinopathy.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Recent evidence suggests that simultaneous inhibition of multiple diabetes-induced molecular abnormalities is a valuable approach toward inhibiting the development of early stages of diabetic retinopathy (DR). The methylxanthine, theophylline acts by multiple mechanisms in different diseases, and we investigated its effect on the development of lesions of early DR. Methods: Wild-type C57Bl/6J male mice were made diabetic with streptozotocin at two to three months of age, and some were given theophylline or structurally related analogs for one to two months to assess effects on visual function and biochemical and physiological abnormalities in the retina, or for eight months to assess retinal vascular histopathology. Effects of theophylline on leukocytes were examined ex vivo, because leukocytes contribute to the retinal vascular pathology of diabetes. Results: Retinal superoxide generation, expression of inflammatory proteins, leukocyte-mediated cytotoxicity against retinal endothelial cells, and degeneration of retinal capillaries were significantly increased in retinas of control diabetic mice, and theophylline inhibited each of these abnormalities. Of recognized actions of theophylline (adenosine receptor antagonist, antioxidant and anti-inflammatory agent, inducer of histone deacetylase activity, inhibitor of phosphodiesterases), the inhibition of phosphodiesterases, oxidative stress and inflammation seem most likely to account for the beneficial effects of the drug in DR. In contrast to the beneficial effect of theophylline on capillary degeneration, it did not inhibit the diabetes-induced dysfunction of the neural retina. Conclusions: Theophylline significantly inhibited the degeneration of retinal capillaries in early DR and can help investigate mechanistic differences in the pathogenesis of retinal capillary degeneration and neural dysfunction in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.